WCM
JANX icon

Winthrop Capital Management’s Janux Therapeutics JANX Stock Holding History

Winthrop Capital Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,327
Closed -$106K – 378
2025
Q3 		$106K Buy
+4,327
New +$105K 0.03% 141

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Winthrop Capital Management's JANX Position: Q4 2025 in Review

Winthrop Capital Management sold out of Janux Therapeutics (JANX) in Q4 2025, closing a stake of 4,327 shares — an estimated $106K sold.

Winthrop Capital Management first reported a position in JANX in Q3 2025 and held it in 1 quarter. The position peaked at $106K in Q3 2025. 176 funds tracked by Wall St. Rank hold JANX as of Q4 2025.

  • Winthrop Capital Management reported no remaining Janux Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Winthrop Capital Management sold 4,327 Janux Therapeutics shares in Q4 2025, an estimated $106K.
  • Winthrop Capital Management first reported a position in Janux Therapeutics in Q3 2025 and held it in 1 quarter.
  • Winthrop Capital Management's Janux Therapeutics position peaked at $106K in Q3 2025.
  • 176 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2025.

Based on Winthrop Capital Management's 13F filing for Q4 2025, filed 10 Feb 2026.